[go: up one dir, main page]

NO975560L - Fremgangsmåte for å redusere bentap - Google Patents

Fremgangsmåte for å redusere bentap

Info

Publication number
NO975560L
NO975560L NO975560A NO975560A NO975560L NO 975560 L NO975560 L NO 975560L NO 975560 A NO975560 A NO 975560A NO 975560 A NO975560 A NO 975560A NO 975560 L NO975560 L NO 975560L
Authority
NO
Norway
Prior art keywords
bone loss
pyrrolidinyl
alkyl
compound
formula
Prior art date
Application number
NO975560A
Other languages
English (en)
Other versions
NO975560D0 (no
Inventor
George Joseph Cullinan
Steven A Fontana
Robin S L Fuchs-Young
Andrew Lawrence Glasebrook
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of NO975560D0 publication Critical patent/NO975560D0/no
Publication of NO975560L publication Critical patent/NO975560L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

Foreliggende oppfinnelse beskriver en fremgangsmåte for å begrense bentapeffekten ved en forbindelse med formel I hvori R er -CH2CON(CH3)-n-CH2CH2CH2CH3 eller - SO(CH2)3CF2CF3, eller et farmasøytisk akseptabelt salter derav, og hvori formel I forbindelsen ble administrert til et pattedyr som har behov for behandling, og omfatter samtidig eller etterfølgende administrering til dette pattedyr av en effektiv mengde av en forbindelse med formel II hvori hver R1 er uavhengig av hverandre -H, -OH, -0(C!-C4 alkyl), -OCOC6H5, - OCO(C,-C6 alkyl) eller -OSO2(C4-C6 alkyl); og R2 er 1-piperidinyl, 1-pyrrolidinyl, metyl-1-pyrrolidinyl, dimetyl-1-pyrrolidinyl, 4-morfolino, dimetylamino, dietylamino eller 1-heksametylenimino; eller et farmasøytisk akseptabelt salt derav. Det ble også beskrevet en fremgangsmåte for å begrense bentap indusert ved administrering av formel (I) forbindelsen som omfatter samtidig eller etterfølgende administrering av et benanabolt middel. Det ble også beskrevet farmasøytiske sammensetninger.
NO975560A 1995-06-06 1997-12-02 Fremgangsmåte for å redusere bentap NO975560L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US47111195A 1995-06-06 1995-06-06
PCT/US1996/008810 WO1996039141A1 (en) 1995-06-06 1996-06-05 Methods for minimizing bone loss

Publications (2)

Publication Number Publication Date
NO975560D0 NO975560D0 (no) 1997-12-02
NO975560L true NO975560L (no) 1998-01-26

Family

ID=23870302

Family Applications (1)

Application Number Title Priority Date Filing Date
NO975560A NO975560L (no) 1995-06-06 1997-12-02 Fremgangsmåte for å redusere bentap

Country Status (27)

Country Link
EP (1) EP0747056B1 (no)
JP (1) JP2001501907A (no)
KR (1) KR19990022497A (no)
CN (1) CN1239429A (no)
AR (2) AR003134A1 (no)
AT (1) ATE187643T1 (no)
AU (1) AU696927B2 (no)
BR (1) BR9608390A (no)
CA (1) CA2223174A1 (no)
CO (1) CO4700447A1 (no)
CZ (1) CZ383097A3 (no)
DE (1) DE69605600T2 (no)
DK (1) DK0747056T3 (no)
EA (1) EA199800014A1 (no)
ES (1) ES2142545T3 (no)
GR (1) GR3032863T3 (no)
HU (1) HUP9900854A3 (no)
IL (1) IL118573A (no)
NO (1) NO975560L (no)
PE (1) PE2298A1 (no)
PL (1) PL323941A1 (no)
PT (1) PT747056E (no)
SI (1) SI0747056T1 (no)
TR (1) TR199701508T1 (no)
WO (1) WO1996039141A1 (no)
YU (1) YU34296A (no)
ZA (1) ZA964681B (no)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001509010A (ja) * 1996-11-22 2001-07-10 アクゾ・ノベル・エヌ・ベー Ｂｍｐ―４プロモーターならびに骨粗鬆症の予防および／または治療用の治療剤のスクリーニングにおけるその用途
GB2324726A (en) * 1997-05-01 1998-11-04 Merck & Co Inc Combination Therapy for the Treatment of Osteoporosis
US6096764A (en) * 1997-08-21 2000-08-01 Eli Lilly And Company Methods for inhibiting detrimental side-effects due to GnRH of GnRH agonist administration
US7005428B1 (en) 1998-06-11 2006-02-28 Endorecherche, Inc. Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4895715A (en) * 1988-04-14 1990-01-23 Schering Corporation Method of treating gynecomastia
US5393785A (en) * 1988-10-31 1995-02-28 Endorecherche, Inc. Therapeutic antiestrogens
US5482949A (en) * 1993-03-19 1996-01-09 Eli Lilly And Company Sulfonate derivatives of 3-aroylbenzo[b]thiophenes
DE4329344A1 (de) * 1993-08-27 1995-03-02 Schering Ag Progesteronantagonistisch- und antiöstrogen wirksame Verbindungen für die Behandlung des Leiomyomata uteri

Also Published As

Publication number Publication date
CO4700447A1 (es) 1998-12-29
KR19990022497A (ko) 1999-03-25
NO975560D0 (no) 1997-12-02
PT747056E (pt) 2000-05-31
AU696927B2 (en) 1998-09-24
YU34296A (en) 1999-11-22
CN1239429A (zh) 1999-12-22
AR003134A1 (es) 1998-07-08
WO1996039141A1 (en) 1996-12-12
ATE187643T1 (de) 2000-01-15
ES2142545T3 (es) 2000-04-16
BR9608390A (pt) 1999-05-04
PL323941A1 (en) 1998-04-27
EP0747056A2 (en) 1996-12-11
CZ383097A3 (cs) 1998-09-16
IL118573A (en) 2000-01-31
EA199800014A1 (ru) 1998-06-25
DE69605600T2 (de) 2000-05-31
EP0747056B1 (en) 1999-12-15
DE69605600D1 (de) 2000-01-20
GR3032863T3 (en) 2000-07-31
AR003002A1 (es) 1998-05-27
TR199701508T1 (xx) 1998-03-21
CA2223174A1 (en) 1996-12-12
JP2001501907A (ja) 2001-02-13
PE2298A1 (es) 1998-02-28
SI0747056T1 (en) 2000-06-30
HUP9900854A3 (en) 2000-03-28
ZA964681B (en) 1997-12-05
AU5981696A (en) 1996-12-24
EP0747056A3 (en) 1997-03-05
DK0747056T3 (da) 2000-05-01
IL118573A0 (en) 1996-10-16
HUP9900854A2 (hu) 1999-08-30

Similar Documents

Publication Publication Date Title
US5773472A (en) Method and means for prevention of cataract
NO20063382L (no) Nye kinolinderivater
NO975581L (no) Fremgangsmåte for å redusere bentap
PT703228E (pt) Compostos de naftilo intermediarios processos composicoes que os envolvem
AR002964A1 (es) Compuestos de 1(4-hidroxifenil)-2-fenoxi-naftilo, procedimiento para prepararlos, composiciones farmaceuticas que los contienen y compuestosintermediarios de aplicacion en dicho procedimiento.
PT958296E (pt) Compostos heterociclicos processo para a sua preparacao composicoes farmaceuticas contendo-os e sua utilizacao no tratamento da diabetes e doencas relacionadas
KR950700265A (ko) 고지혈증 치료에 유용한 벤조티아제핀 화합물(hypolipidaemic ben zothiazepine compounds)
NO950774L (no) Fremgangsmåte for inhibering av bentap og nedsettelse av serumkolesterol
AR003930A1 (es) Procedimiento para preparar compuestos de 2-fenil-3-fenoxi o feniltio-benzotiofeno y sales farmaceuticamente aceptables, compuestos intermediarios de aplicación exclusiva en dicho procedimiento y metodo para preparar los compuestos intermediarios mencionados
KR960701033A (ko) 효능있는 칼슘 길항 및 산화방지 활성을 모두 갖는 화합물, 및 세포보호제로서 그것의 사용방법(compounds having both potent calcium antagonist and antioxidant activity and use there of as cytoprotective agents)
YU2300A (sh) Derivati supstituisanog 1,2,3,4-tetrahidronaftalina
RU94045149A (ru) Средство ингибирования легочных гипертонических заболеваний
ES2141957T3 (es) Uso de raloxifeno y sus analogos para la produccion de un medicamento para el tratamiento de enfermedades virales.
KR950032267A (ko) 11,21-비스페닐-19-노르프레그난 유도체
DE69628246D1 (de) Naphthyl- und Dihydronaphthylverbindungen als Arzneimittel
NO20002099L (no) 6,11-bro-erytromycinderivater
BR9812239A (pt) Composto, formulação farmacêutica, uso do composto, processos para o tratamento de distúrbios, para o tratamento de distúrbios mediados por 5-hidroxitriptamina, e, para a preparação do composto
MY106401A (en) N-imidazolyl-and-n-imidazolymethyl-derivatives of substituted bicyclic compounds.
NO944933L (no) Fremgangsmåte for å inhibere sykdomstilstander i brystet
NO975560L (no) Fremgangsmåte for å redusere bentap
NO20060277L (no) Anvendelse av bisyklo [2.2.1] heptanderivater til fremstilling av nevrobeskyttende farmasoytiske sammensetninger
NO971229D0 (no) Fremgangsmåte for minimalisering av den uterotrofiske effekt av tamoxifen og tamoxifenanaloger
AU2015259752B2 (en) Reduced central corneal thickening by use of hydrophilic ester prodrugs of beta-chlorocyclopentanes
NO994902L (no) Forebygging av brystkreft ved selektive östrogenreseptormodulatorer
ATE206431T1 (de) Antifungal fusacandine